| VIS ID | Virus | Ensembl ID | Gene Type | Target Gene | Oncogene | Tumor Suppressor Gene | NCBI ID | Uniprot ID |
|---|---|---|---|---|---|---|---|---|
| TVIS10046591 | HBV | ENSG00000022355.18 | protein_coding | GABRA1 | No | No | 2554 | P14867 |
| TVIS30082845 | HIV | ENSG00000022355.18 | protein_coding | GABRA1 | No | No | 2554 | P14867 |
Target Gene Table
▼
TCGA Plot Options
▼
Drug Information
▼
| Gene | GABRA1 |
|---|---|
| DrugBank ID | DB01496 |
| Drug Name | Dihydro-2-thioxo-5-((5-(2-(trifluoromethyl)phenyl)-2-furanyl)methyl)-4,6(1H,5H)-pyrimidinedione |
| Target ID | BE0000795 |
| UniProt ID | P14867 |
| Regulation Type | potentiator |
| PubMed IDs | 14579514; 10209232; 11264449; 10487207 |
| Citations | Whiting PJ: The GABAA receptor gene family: new opportunities for drug development. Curr Opin Drug Discov Devel. 2003 Sep;6(5):648-57.@@Mehta AK, Ticku MK: An update on GABAA receptors. Brain Res Brain Res Rev. 1999 Apr;29(2-3):196-217.@@Yamakura T, Bertaccini E, Trudell JR, Harris RA: Anesthetics and ion channels: molecular models and sites of action. Annu Rev Pharmacol Toxicol. 2001;41:23-51.@@Krasowski MD, Harrison NL: General anaesthetic actions on ligand-gated ion channels. Cell Mol Life Sci. 1999 Aug 15;55(10):1278-303. |
| Groups | Experimental; Illicit |
| Direct Classification | Trifluoromethylbenzenes |
| SMILES | FC(F)(F)C1=CC=CC=C1C1=CC=C(CC2C(=O)NC(=S)NC2=O)O1 |
| Pathways | |
| PharmGKB | |
| ChEMBL |
« Prev123456789101112131415161718192021222324252627282930313233343536373839404142434445464748495051525354555657585960616263646566676869707172737475767778798081828384858687888990919293949596979899100101102103104105106107108109110111112113114115116117118119120121122123124125126127128129130131132133134135136137138139140141142143144145146147148149150151152153154155156157158159160161162163Next »
